Felix Sterling
Child & Adolescent Psychiatry · Brooklyn, NYNPI 1801066907
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,050 of the $6,208 with a category attached, or 81.4%. It is spread thinly across 19 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,829 and has fallen 88.8% since, to $205 in 2025. Among child & adolescent psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 197 payments — averaging $31.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Merck$1K
- Alkermes, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$573
- Neurocrine Biosciences, Inc.$514
- Amgen$375
- plus $1K from 13 others
What the payments were for
- Grants$1,15319%
- Food & beverage$5,05081%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 72 | $1,309 |
| Merck | 1 | $1,153 |
| Alkermes, Inc. | 38 | $1,046 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $573 |
| Neurocrine Biosciences, Inc. | 14 | $514 |
| Amgen | 3 | $375 |
| Lundbeck LLC | 15 | $276 |
| AbbVie(2 entities) | 15 | $248 |
| Johnson & Johnson | 2 | $163 |
| E.r. Squibb & Sons, L.L.C. | 2 | $155 |
| Teva Pharmaceuticals USA, Inc. | 2 | $141 |
| Biohaven Pharmaceuticals, Inc. | 1 | $71 |
| Abbott | 2 | $49 |
| Bridgebio Pharma, Inc. | 3 | $48 |
| Avanos Medical | 1 | $25 |
| Biocompatibles, Inc. | 1 | $17 |
| Amryt Pharma Holdings Ltd | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Altathera Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,208 in reported general payments places this provider in the 90th percentile of 317 child & adolescent psychiatry providers in New York.
See all child & adolescent psychiatry providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 15 | $20,694 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $20,576 |
| Divalproex Sodium ErDivalproex Sodium | 36 | $2,423 |
| Quetiapine Fumarate | 171 | $1,337 |
| Escitalopram Oxalate | 223 | $958 |
| Aripiprazole | 57 | $936 |
| Mirtazapine | 85 | $670 |
| Alprazolam | 77 | $548 |
| Haloperidol | 17 | $471 |
| Olanzapine | 14 | $404 |
| Lithium Carbonate ErLithium Carbonate | 30 | $374 |
| Duloxetine Hcl | 25 | $368 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 40 | $363 |
| Bupropion Hcl | 24 | $356 |
| Bupropion XlBupropion Hcl | 24 | $338 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $163 | $20,69415 claims |
| Alkermes, Inc.Lybalvi | $1,046 | $20,57614 claims |
| Lilly USA, LLCOlanzapine | $15 | $40414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 317 child & adolescent psychiatry providers in New York.
Other child & adolescent psychiatry in Brooklyn
- Marie CharlesBrooklyn$11K
- Fahim QureshiBrooklyn$6K
- Faina YablochnikovaBrooklyn$3K
- Zu FashanBrooklyn$3K
- Mirielle DupervalBrooklyn$2K
- Mastan LokireddyBrooklyn$2K
- Manoj ShahBrooklyn$1K
- Matthew LorberNew York$398K
- Mitchell CabisudoNew Windsor$346K
- Parinda ParikhWhite Plains$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.